Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017-2018.
Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017-2018.
复制标题
DOI：
10.1186/s12936-021-03585-6
复制
发表时间：
2021-01-19
期刊：
影响因子：
3
通讯作者：
Valea I
中科院分区：
文献类型：
--
作者：
Gansané A;Moriarty LF;Ménard D;Yerbanga I;Ouedraogo E;Sondo P;Kinda R;Tarama C;Soulama E;Tapsoba M;Kangoye D;Compaore CS;Badolo O;Dao B;Tchwenko S;Tinto H;Valea I
The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight against malaria. This study evaluated the efficacy of two artemisinin-based combinations recommended to treat uncomplicated Plasmodium falciparum malaria in Burkina Faso in three sites: Niangoloko, Nanoro, and Gourcy. This was a two-arm randomized control trial of the efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP). Children aged 6–59 months old were monitored for 42 days. The primary outcomes of the study were uncorrected and PCR-corrected efficacies to day 28 for AL and 42 for DP. Molecular markers of resistance to artemisinin derivatives and partner drugs were also analysed. Of 720 children enrolled, 672 reached study endpoints at day 28, 333 in the AL arm and 339 in the DP arm. PCR-corrected 28-day per protocol efficacy in the AL arm was 74% (64–83%) in Nanoro, 76% (66–83%) in Gourcy, and 92% (84–96%) in Niangoloko. The PCR-corrected 42-day per protocol efficacy in the DP arm was 84% (75–89%) in Gourcy, 89% (81–94%) in Nanoro, and 97% (92–99%) in Niangoloko. No Pfk13 mutation previously associated with artemisinin-resistance was observed. No statistically significant association was found between treatment outcome and presence of the 86Y mutation in the Pfmdr1 gene. There was also no association observed between treatment outcome and Pfpm2 or Pfmdr1 copy number variation. The results of this study indicate evidence of inadequate efficacy of AL at day 28 and DP at day 42 in the same two sites. A change of first-line ACT may be warranted in Burkina Faso. Trial Registry Pan African Clinical Trial Registry Identifier: PACTR201708002499311. Date of registration: 8/3/2017 https://pactr.samrc.ac.za/Search.aspx
登录
查看更多内容
DOI：
10.1016/s1473-3099(17)30365-1
发表时间：
2017-12
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Koita OA;Sangaré L;Miller HD;Sissako A;Coulibaly M;Thompson TA;Fongoro S;Diarra Y;Ba M;Maiga A;Diallo B;Mushatt DM;Mather FJ;Shaffer JG;Anwar AH;Krogstad DJ
通讯作者：
Krogstad DJ
影响因子：
3
作者：
Diallo A;Sié A;Sirima S;Sylla K;Ndiaye M;Bountogo M;Ouedraogo E;Tine R;Ndiaye A;Coulibaly B;Ouedraogo A;Faye B;Ba EH;Compaore G;Tiono A;Sokhna C;Yé M;Diarra A;Bahmanyar ER;De Boer M;Pirçon JY;Usuf EA
通讯作者：
Usuf EA
与柬埔寨恶性疟原虫疟疾双氢青蒿素-哌喹失败相关的遗传标记：基因型-表型关联研究。
DOI：
10.1016/s1473-3099(16)30409-1
发表时间：
2017-03
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Amato R;Lim P;Miotto O;Amaratunga C;Dek D;Pearson RD;Almagro-Garcia J;Neal AT;Sreng S;Suon S;Drury E;Jyothi D;Stalker J;Kwiatkowski DP;Fairhurst RM
通讯作者：
Fairhurst RM
DOI：
10.3185/pathexo3235
发表时间：
2009-02-01
期刊：
Bulletin de la Societe de pathologie exotique (1990)
影响因子：
--
作者：
Gansane, A;Nebie, I;Sirima, B S
通讯作者：
Sirima, B S
影响因子：
9.3
作者：
Denoeud-Ndam L;Dicko A;Baudin E;Guindo O;Grandesso F;Diawara H;Sissoko S;Sanogo K;Traoré S;Keita S;Barry A;de Smet M;Lasry E;Smit M;Wiesner L;Barnes KI;Djimde AA;Guerin PJ;Grais RF;Doumbo OK;Etard JF
通讯作者：
Etard JF